Skip to main content
SpringerLink
Log in

Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The effectiveness and long-term tolerability of a new formulation of bromocriptine with slow gastrointestinal release (Parlodel SRO) has been evaluated on ten patients with macroprolactinoma, seven patients with microprolactinoma and five patients with nontumoral hyperprolactinemia during a period of 1–30 months. Six out of ten macroprolactinoma-bearing patients obtained a rapid normalization of plasma PRL levels with reduction of the tumor size recorded by CT scan follow-up. Four of six microprolactinomas and all the five nontumoral hyperprolactinemic patients became normoprolactinemic with recovery of gonadal functions while in two other microprolactinomas Parlodel SRO significantly reduced plasma PRL levels with restoration of menses. Only in two patients the treatment was withdrawn for the appearance of side effects. In conclusion, Parlodel SRO is an effective drug in the management of tumoral and nontumoral hyperprolactinemia. The good long-term tolerability together with the hypoprolactinemic activity makes this drug a very good choice therapy in hyperprolactinemic syndromes even in case of poor tolerability to the standard formulation of the drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thorner M.O., McNeilly A.S., Hagan C., Besser G.M. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br. Med. J. 2: 419, 1974.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Thorner M.O., Fluckinger E., Calne D.B. Bromocriptine, a clinical and pharmacological review. Raven Press, 143, 1980.

  3. Liuzzi A., Dallabonzana D., Oppizzi G., Verde G.G., Cozzi R., Chiodini P.G., Luccarelli G. Low doses of dopamine-agonists in the long-term treatment of macroprolactinomas. N. Engl. J.Med. 313: 656, 1985.

    Article  CAS  PubMed  Google Scholar 

  4. Warfield A., Finkel D.M., Schanz N.J., Savimo P.J., Snyder P.J. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function. Ann. Intern. Med. 101: 783, 1984.

    Article  CAS  PubMed  Google Scholar 

  5. Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang R.J., Chang R.J., Jaffe R., Joplin J., Tyson J., Thorner M.O. The Bromocriptine Study Group. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicentric study. J. Clin. Endocrinol. Metab. 60: 698, 1985.

    Article  CAS  PubMed  Google Scholar 

  6. McGregor A.M., Scanion M.F., Hall R., Hall K. Effects of bromocriptine on pituitary tumour size. Br. Med. J. 2: 700, 1979.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Landolt A.M., Wutrich R., Fellmann M. Regression of pituitary prolactinoma after treatment with bromocriptine. Lancet 1: 1082, 1979.

    Article  CAS  PubMed  Google Scholar 

  8. Thorner M.O., Martin W.H., Rogol A.D., Morris J.L., Perryman R.L., Conway B.P., Howards S.S., Wolfman M.G., MacLeod R.M. Rapid regression of pituitary prolactinomas during bromocriptine treatment. J. Clin. Endocrinol. Metab. 51: 438, 1980.

    Article  CAS  PubMed  Google Scholar 

  9. Spark R.F., Baker R., Bienpang B.C., Bergland R. Bromocriptine reduces pituitary tumor size and hypersecretion. Requiem for pituitary surgery? JAMA 247: 311, 1982.

    Article  CAS  PubMed  Google Scholar 

  10. Merola B., Colao A., Caruso E., Cataldi M., Sarnacchiaro F., Lombardi G., Schettini G. Parlodel LAR and Parlodel SRO on tumoral and nontumoral hyperprolactinemia: 2 year follow-up. J. Endocrinol. Invest. 13 (Suppl. 2): 135, 1990 (Abstract).

    Google Scholar 

  11. Moro M., Maraschini C., Toja P., Masala A., Alagna S., Rovasio P.P., Ginanni A., Lancranja I., Cavagnini P, Comparison between a slow release oral preparation of bromocriptine and regular bromocriptine in patientswith hyperprolactinemia: a double blind, double dummy study. Horm. Res. 35: 137, 1991.

    Article  CAS  PubMed  Google Scholar 

  12. Ferrari C., Mattei A., Melis G.B., Paracchi A., Muratori M., Faglia G., Schedoni D., Crosignani P.G. Cabergoline: Long-acting oral treatment of hyper-prolactinemic disorders. J. Clin. Endocrinol. Metab. 68: 1201, 1989.

    Article  CAS  PubMed  Google Scholar 

  13. Khalfallah Y., Claustrat B., Grochowicki M., Flocard F., Horlait S., Serusclat P., Sassolas G. Effects of a new prolactin inhibitor, CV 205–502, in the treatment of human macroprolactinomas. J. Clin Endocrinol. Metab. 71: 354, 1990.

    Article  CAS  PubMed  Google Scholar 

  14. Schettini G., Lombardi G., Merola B., Colao A., Miletto P., Caruso E., Lancranjan I. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long acting repeatable form of bromocriptine (Parlodel LAR). Clin. Endocrinol. (Oxf.) 33: 161, 1990.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cattedra di Endocrinologia, Università di Napoli, Italy

    B. Merola, A. Colao, E. Caruso, F. Sarnacchiaro & G. Lombardi

  2. Istituto di Farmacologia Sperimentale e Clinica, Il School of Medicine, Università di Napoli, Via S. Pansini 5, 80131, Napoli, Italy

    G. Schettini

  3. Department of Neuroendocrinology, Clinical Research, Sandoz Ltd, Basle, Switzerland

    I. Lancranjan

Authors
  1. B. Merola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Caruso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Sarnacchiaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Lancranjan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Schettini
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Merola, B., Colao, A., Caruso, E. et al. Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia. J Endocrinol Invest 15, 173–176 (1992). https://doi.org/10.1007/BF03348700

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03348700

Key-words

Search

Navigation